• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.吉妥珠单抗奥唑米星用于急性髓系白血病婴儿患者：儿童肿瘤协作组试验AAML03P1和AAML0531的结果
Blood. 2017 Aug 17;130(7):943-945. doi: 10.1182/blood-2017-01-762336. Epub 2017 Jul 3.
2
Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis.吉妥珠单抗奥佐米星治疗新诊断的急性髓系白血病：系统评价和荟萃分析。
Br J Haematol. 2013 Nov;163(3):315-25. doi: 10.1111/bjh.12528. Epub 2013 Aug 23.
3
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.AAML03P1 研究：吉妥珠单抗奥唑米星联合化疗治疗新诊断儿童急性髓系白血病的安全性初探：来自儿童肿瘤协作组的报告。
Cancer. 2012 Feb 1;118(3):761-9. doi: 10.1002/cncr.26190. Epub 2011 Jul 15.
4
The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.在成年急性髓系白血病患者的化疗中添加吉妥珠单抗奥佐米星。
Expert Rev Anticancer Ther. 2016;16(4):377-82. doi: 10.1586/14737140.2016.1162099. Epub 2016 Mar 21.
5
Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.吉妥珠单抗奥唑米星（麦罗塔）联合化疗方案治疗急性髓性白血病的试验。
Clin Lymphoma. 2002 Mar;2 Suppl 1:S24-8. doi: 10.3816/clm.2002.s.005.
6
Potential biomarker for acute myeloid leukaemia therapy.急性髓系白血病治疗的潜在生物标志物。
Lancet Oncol. 2017 Aug;18(8):e438. doi: 10.1016/S1470-2045(17)30507-7. Epub 2017 Jun 29.
7
Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.添加吉妥珠单抗奥佐米星到新诊断的急性髓系白血病诱导化疗中的效果：前瞻性随机 III 期试验的荟萃分析。
Ann Oncol. 2014 Feb;25(2):455-61. doi: 10.1093/annonc/mdt566.
8
Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.小儿急性髓系白血病临床试验中不良事件确定的准确性
J Clin Oncol. 2016 May 1;34(13):1537-43. doi: 10.1200/JCO.2015.65.5860. Epub 2016 Feb 16.
9
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.吉妥单抗奥唑米星用于初治急性髓系白血病儿童和青少年可通过降低复发风险提高无事件生存期：儿童肿瘤学组III期随机试验AAML0531的结果
J Clin Oncol. 2014 Sep 20;32(27):3021-32. doi: 10.1200/JCO.2014.55.3628.
10
Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.分次给予吉妥珠单抗奥佐米星联合 3+7 诱导化疗作为首次复发的年轻急性髓系白血病患者的挽救治疗。
Ann Hematol. 2012 Dec;91(12):1871-7. doi: 10.1007/s00277-012-1528-9. Epub 2012 Jul 21.

引用本文的文献

1
Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.儿童肿瘤学组 2023 年研究蓝图：髓系肿瘤。
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30584. doi: 10.1002/pbc.30584. Epub 2023 Jul 21.
2
Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin.治疗儿童患者中CD33阳性初发急性髓系白血病：聚焦吉妥珠单抗奥唑米星的临床价值
Onco Targets Ther. 2023 Apr 29;16:297-308. doi: 10.2147/OTT.S263829. eCollection 2023.
3
Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios.伴有高 FLT3/ITD 等位基因比的小儿急性髓系白血病患者的预后不良。
Nat Commun. 2022 Jun 27;13(1):3679. doi: 10.1038/s41467-022-31489-9.
4
Immune-Based Approaches for the Treatment of Pediatric Malignancies.基于免疫的小儿恶性肿瘤治疗方法
Annu Rev Cancer Biol. 2020 Mar;4:353-370. doi: 10.1146/annurev-cancerbio-030419-033436.
5
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric -Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.吉妥珠单抗奥佐米星可改善儿童 - 重现 AML 的无事件生存并降低复发率：来自 III 期儿童肿瘤组试验 AAML0531 的结果。
J Clin Oncol. 2021 Oct 1;39(28):3149-3160. doi: 10.1200/JCO.20.03048. Epub 2021 May 28.
6
Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a -Rearranged Leukemia.病例报告：靶向两种抗原作为混合表型急性白血病的一种有前景的策略：在一名伴有α重排白血病的婴儿中，blinatumomab与吉妥珠单抗奥唑米星联合应用
Front Oncol. 2021 Feb 26;11:637951. doi: 10.3389/fonc.2021.637951. eCollection 2021.
7
Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia.急性白血病婴儿的表现敏锐度、诱导死亡率和资源利用。
Pediatr Blood Cancer. 2021 Jul;68(7):e28940. doi: 10.1002/pbc.28940. Epub 2021 Mar 11.
8
Acute Leukemia in Infants.婴儿急性白血病。
Curr Oncol Rep. 2021 Feb 12;23(3):27. doi: 10.1007/s11912-021-01021-1.

本文引用的文献

1
Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force.婴儿抗癌药物的给药：儿童肿瘤学组化疗标准化特别工作组的当前方法及建议
Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26636. Epub 2017 May 16.
2
Classification of treatment-related mortality in children with cancer: a systematic assessment.癌症患儿治疗相关死亡率的分类：系统评估。
Lancet Oncol. 2015 Dec;16(16):e604-10. doi: 10.1016/S1470-2045(15)00197-7.
3
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.吉妥单抗奥唑米星用于初治急性髓系白血病儿童和青少年可通过降低复发风险提高无事件生存期：儿童肿瘤学组III期随机试验AAML0531的结果
J Clin Oncol. 2014 Sep 20;32(27):3021-32. doi: 10.1200/JCO.2014.55.3628.
4
Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002/01 protocol have an outcome comparable to that of older children.按照意大利儿科学血液学与肿瘤学协会2002/01方案治疗的急性髓系白血病婴儿，其治疗结果与大龄儿童相当。
Haematologica. 2014 Aug;99(8):e127-9. doi: 10.3324/haematol.2014.106526. Epub 2014 May 16.
5
Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.诱导治疗中适当的剂量减少对于治疗急性髓细胞白血病的婴儿至关重要：来自日本儿科白血病/淋巴瘤研究组的报告。
Int J Hematol. 2013 Nov;98(5):578-88. doi: 10.1007/s12185-013-1429-2. Epub 2013 Sep 26.
6
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.吉妥珠单抗奥佐米星可降低儿童急性髓系白血病患者的微小残留病。
Cancer. 2013 Nov 15;119(22):4036-43. doi: 10.1002/cncr.28334. Epub 2013 Sep 4.
7
Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004.吉妥珠单抗奥佐米星作为巩固治疗不能预防 AML 患儿复发：来自 NOPHO-AML 2004 的结果。
Blood. 2012 Aug 2;120(5):978-84. doi: 10.1182/blood-2012-03-416701. Epub 2012 Jun 22.
8
Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report.强化一线和二线治疗后婴儿 AML 的良好结局：AML-BFM 研究组报告。
Leukemia. 2012 Apr;26(4):654-61. doi: 10.1038/leu.2011.267. Epub 2011 Oct 4.
9
Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.急性髓细胞白血病患儿的随机试验结果：医学研究委员会 AML12 试验。
Br J Haematol. 2011 Nov;155(3):366-76. doi: 10.1111/j.1365-2141.2011.08851.x. Epub 2011 Sep 9.
10
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.AAML03P1 研究：吉妥珠单抗奥唑米星联合化疗治疗新诊断儿童急性髓系白血病的安全性初探：来自儿童肿瘤协作组的报告。
Cancer. 2012 Feb 1;118(3):761-9. doi: 10.1002/cncr.26190. Epub 2011 Jul 15.

Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.

作者信息

Guest Erin M, Aplenc Richard, Sung Lillian, Raimondi Susana C, Hirsch Betsy A, Alonzo Todd A, Gerbing Robert B, Wang Yi-Cheng Jim, Kahwash Samir B, Heerema-McKenney Amy, Meshinchi Soheil, Gamis Alan S

机构信息

Children's Mercy Kansas City, Kansas City, MO.

Children's Hospital of Philadelphia, Philadelphia, PA.

出版信息

Blood. 2017 Aug 17;130(7):943-945. doi: 10.1182/blood-2017-01-762336. Epub 2017 Jul 3.

DOI:10.1182/blood-2017-01-762336
PMID:28674028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5561899/
Abstract
摘要